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Activation of the T cell receptor (TCR) on the T cell through ligation with antigen-MHC
complex of an antigen-presenting cell (APC) is an essential process in the activation of
T cells and induction of the subsequent adaptive immune response. Upon activation,
the TCR, together with its associated co-receptor CD3 complex, assembles in signaling
microclusters that are transported to the center of the organizational structure at the
T cell-APC interface termed the immunological synapse (IS). During IS formation, local
cell surface receptors and associated intracellular molecules are reorganized, ultimately
creating the typical bull’s eye-shaped pattern of the IS. CD6 is a surface glycoprotein
receptor, which has been previously shown to associate with CD3 and co-localize
to the center of the IS in static conditions or stable T cell-APC contacts. In this
study, we report the use of different experimental set-ups analyzed with microscopy
techniques to study the dynamics and stability of CD6-TCR/CD3 interaction dynamics
and stability during IS formation in more detail. We exploited antibody spots, created
with microcontact printing, and antibody-coated beads, and could demonstrate that
CD6 and the TCR/CD3 complex co-localize and are recruited into a stimulatory cluster
on the cell surface of T cells. Furthermore, we demonstrate, for the first time, that
CD6 forms microclusters co-localizing with TCR/CD3 microclusters during IS formation
on supported lipid bilayers. These co-localizing CD6 and TCR/CD3 microclusters are
both radially transported toward the center of the IS formed in T cells, in an actin
polymerization-dependent manner. Overall, our findings further substantiate the role
of CD6 during IS formation and provide novel insight into the dynamic properties
of this CD6-TCR/CD3 complex interplay. From a methodological point of view, the
biophysical approaches used to characterize these receptors are complementary
and amenable for investigation of the dynamic interactions of other membrane
receptors.
Keywords: T cell, immunological synapse, T-cell receptor (TCR), CD3, CD6, membrane receptor, receptor
dynamics
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INTRODUCTION
T cells play an important role in the execution of the adaptive
immune response by regulating the activity of innate and
other adaptive immune cells or directly executing effector
functions, such as killing by cytotoxic T cells. In general,
for T cells to execute their function, they need to become
activated by antigens through interaction with an antigen-
presenting cell (APC). Crucial to this activation is the interaction
between the T cell receptor (TCR) on the T cell surface
and the peptide-Major Histocompatibility Complex (pMHC)
on the APC surface. Immediately after recognition of the
pMHC, the TCR, associated with the CD3 receptor complex,
combines with co-stimulatory receptors CD4/CD8 and CD28
on the T cell membrane in small so-called TCR microclusters
where signaling is initiated (1, 2). During the T cell-APC
contact, TCR microclusters are laterally transported during local
cell surface receptor rearrangement creating a typical bull’s
eye-shaped pattern at the T cell-APC interface, termed “the
immunological synapse” (IS) (3, 4). This lateral TCRmicrocluster
transport results in TCR accumulation in the center of the
IS, forming the central supramolecular activation cluster or
“cSMAC,” together with co-stimulatory molecules such as CD2,
CD4/CD8 and CD28 (4–6). Surrounding the central cSMAC
is the peripheral supramolecular activation cluster (pSMAC),
that exists of adhesion receptor LFA-1 and phosphatase CD45,
both kept from the cSMAC due to size-dependent exclusion
(7). This spatial organization of the receptors, together with the
transport of TCR microclusters toward the cSMAC is dependent
on the actomyosin cytoskeleton, which is excluded from the
cSMAC region (8–11). Antigen binding on the extracellular side
leads intracellularly to recruitment of tyrosine kinase Lck to the
TCR/CD3 complex, where it phosphorylates immunoreceptor
tyrosine-based activation motifs (ITAMs) on the cytoplasmic
tail of CD3 chains (12). Subsequently, tyrosine kinase ZAP70
can bind to the phosphorylated ITAM-motifs and recruit the
transmembrane protein LAT (12, 13). LAT forms a signaling hub,
the so-called LAT signalosome, which through various signaling
molecules such as SLP-76 and GRB2, initiates downstream
events, such as calcium fluxing, actin reorganization, integrin
inside-out signaling and gene expression, leading to T cell
activation and effector functions (12, 14).
CD6 is one of the cell surface co-receptors on the T cell
membrane involved in T cell activation. CD6 is a transmembrane
glycoprotein, part of the scavenger receptor cysteine-rich
superfamily (SRCR-SF), that is expressed on thymocytes, mature
T cells, a subset of B cells and NK cells, and brain parenchymal
cells (15–18). On the T cell membrane, CD6 associates with
its closely related family member CD5 (17, 19). Extracellularly,
ligands for CD6 are Activated Leukocyte Cell AdhesionMolecule
(ALCAM), which is present on antigen presenting cells and
thymic epithelial cells, and the recently identified CD318, a
glycoprotein expressed on epithelial cells, some hematopoietic
cells and mesenchymal stem cells (16, 20–22).
Already early on, it was clear that CD6 was involved in
T cell activation in mature T cells, since monoclonal antibodies
targeting CD6 were able to induce T cell activation, subsequent
T cell proliferation and IL-2 receptor expression (23, 24). Since
then, multiple studies have further substantiated a co-stimulatory
role of CD6 in T cell activation (25–29). However, more recently
this view was challenged by data from Oliveira and colleagues,
who describe a role for CD6 as attenuator of early and late T cell
responses in a ligand-independent manner (30). The exact role
for CD6 in T cell signaling is therefore still under debate andmost
likely depends on a balance between stimulatory and inhibitory
signals, provided among others by binding of its ligand (30, 31).
Multiple data hint at an interaction, either direct or
indirect, between CD6 and the TCR. Co-precipitation studies
have indicated that rat CD6 associates with protein kinases
Lck, Fyn, ZAP-70, and Itk: protein kinases that also interact
with and co-precipitate with the TCR or are part of the
LAT signalosome (14, 32). This interaction is important for
CD6 signaling, as inhibition of protein kinases abolishes
CD6-induced T cell proliferation (26). Furthermore, CD6
physically associates with adaptor protein SLP-76 (33), which
is involved in TCR microcluster signaling. Also, direct cross-
linking of CD3 induces phosphorylation of CD6, which
suggests cross-talk between TCR/CD3 complex and CD6
(34). More importantly, using co-precipitation Gimferrer and
colleagues showed that CD6 and the TCR/CD3 complex
interact (independently of CD5) (35). Also, co-localization of
CD6 and TCR/CD3 in the cSMAC of the mature IS has
been described through co-capping, FRET and DC-T cell co-
cultures (29, 35). CD6 is important for mature IS formation as
treatment with soluble recombinant CD6 leads to inhibition of
IS maturation and resulted in inhibition of T cell proliferation
(35).
Importantly, CD6 has recently reclaimed attention as a
focus of research: the CD6 gene, together with the gene for
its ligand ALCAM, was identified as a susceptibility locus
and a potential target for treatment of multiple sclerosis (36,
37). Furthermore, antibodies targeting CD6 are tested for
treatment of various autoimmune diseases, such as psoriasis
and rheumatoid arthritis (38–41). This renewed interest in
CD6 underlines the importance of understanding CD6 signaling
and interaction at the molecular level. For instance, although
static co-localization of CD6 and TCR/CD3 complexes has
been reported at the fully mature IS and signaling cross-
talk between CD6 and CD3 has been identified, thorough
characterization of (early) dynamics during IS formation and
stability of CD6-TCR/CD3 interplay at the mature IS are still
lacking.
Imaging techniques with high spatiotemporal resolution, such
as Total Internal Reflection Fluorescence (TIRF) Microscopy,
combined with biochemical or immunological assays, such
as supported lipid bilayers (42), have been fundamental in
unraveling the dynamics of multiple protein-protein interactions
during IS formation (1, 11, 13). Here, we exploited different
biophysical approaches including microcontact printing,
fluorescence microscopy techniques, antibody-coated beads and
magnetic tweezers to study the dynamics and stability of CD6-
TCR/CD3 interplay in more detail. Overall, our findings provide
novel insight into the dynamic properties of CD6—TCR/CD3
complex interplay during IS formation.
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MATERIALS AND METHODS
Cell Lines and Transfection
Jurkat E6.1 lymphoma T cells were maintained in 1640 RPMI
(PAA) supplemented with 10% Fetal Calf Serum (Greiner
Bio-one), 1mM Ultra-glutamine (U-glut, PAA) and antibiotics
(100 U/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml
amphotericin B, PAA). Jurkat cell lines stably expressing CD6-
RFP, CD6-GFP, or LifeAct-GFP were obtained by electroporation
using the Neon Transfection System for Electroporation
(Invitrogen) according to the manufacturer’s guidelines. Shortly,
5∗105 Jurkat cells were transfected at 1325 Volt (10ms, 3
pulses) with 3 µg of DNA in 100 µl Resuspension buffer. After
transfection cells were seeded in 2ml of 1640 RPMI with 10%
FCS and 1% U-glut. Antibiotics were added after 3 h. Stable cell
lines were sorted on RFP or GFP expression on a FACSAria cell
sorter (BD Biosciences), and cells were maintained in complete
RPMI medium as described above, additionally supplemented
with 500 ng/ml geneticin (G418, Gibco).
Antibodies, Reagents and Expression
Constructs
The following primary antibodies were used: Mouse IgG2A-
anti-human CD3 antibodies clone T3B and clone OKT-3 (both
referred to in the text as αCD3), and Mouse IgG1 anti-
human LFA-1 antibody TS2/4 were obtained from in-house
hybridoma production. Mouse IgG1 anti-human phospho-
tyrosine (P-Tyr-100), both unconjugated and conjugated to
Alexa488, was obtained from Cell Signaling Technology; Mouse
IgG1 anti-human CD6 (M-T605; referred to in the text as
αCD6) was obtained from BD Biosciences. The following
secondary antibodies were used: Goat anti-Rabbit-IgG(H+L)-
Alexa647 and Goat-anti-Mouse-IgG1-Alexa488 (both from
Invitrogen). Neutravidin-TexasRed was obtained from Thermo
Fisher Scientific. For use in immunofluorescence staining,
anti-CD3 antibody clone OKT-3 was biotinylated (Sulfo-
NHS-LC-Biotin, Thermo Fisher Scientific) at RT for 1.5 h,
with a molecular ratio of IgG:Biotin at 1:15. Following the
same procedure, for use in supported lipid bilayers, anti-
human CD3 antibody OKT-3 was simultaneously biotinylated
and conjugated to ATTO647 Carboxylic Acid, Succinimidyl
ester (ATTO-TEC) at a molecular ratio of IgG:Biotin:dye
at 1:15:15. In both cases, purification was performed with
Zeba Desalting columns (Thermo Fisher Scientific). For
preparation of supported lipid bilayers, the lipids POPC
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and Biotin
Capped PE (1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-
N-[Cap Biotinyl]), both from Avanti Polar Lipids Inc, were
used, together with the fluorescent lipophilic tracer DiI (1,1′-
Dioctadecyl-3,3,3′,3′-Tetramethylindocarbocyanine Perchlorate;
Invitrogen). For inhibition of actin polymerization Cytochalasin
D (CytoD) was used (2.5µg/ml, Sigma-Aldrich). The CD6-GFP
plasmid was generated by cloning CD6 from the CD6-RFP
construct into peGFP-N1 (Clontech) (29). LifeAct-GFP (43) was
a kind gift of Michael Sixt (Institute of Science and Technology,
Vienna, Austria).
Micro Contact Printing of Antibody Spots
PDMS stamps containing a regular pattern of 5µm circular
spots were prepared as described earlier (44). PDMS stamps
were incubated for 1 h at RT with a protein solution containing
15µg/ml Goat-anti-Rabbit IgG(H+L)-Alexa647 antibody to
visualize the spots, and anti-human CD6 or anti-human CD3
clone T3B, the latter including (if indicated) mouse IgG2A
isotype control antibody, to create spots containing 1 or 10%
αCD3. Total concentration of primary antibody in the protein
solution amounted to 100µg/ml. After incubation, the stamps
were thoroughly washed with distilled H2O and dried under
a N2 stream. A glass microscope slide was cleaned by rinsing
consecutively with distilled H2O, 70% ethanol and 100% acetone,
and was dried under a N2 stream. The stamp was then manually
pushed on the cleaned glass microscope slide for 20 s and
removed, after which the stamped area was back-filled with
20µg/ml fibronectin (from human plasma; Roche) in PBS for 1 h
at RT. The microscope slide was washed in PBS and incubated
with 1% BSA for 30min to block all uncoated glass surface. The
slide was subsequently washed with PBS and dried under a N2
stream before cell seeding.
Preparation of Supported Lipid Bilayers
(SLBs)
Coverslips were cleaned in 2% v/v Hellmanex III (Hellma-
Analytics) solution and sonified for 15min at RT after which
they were rinsed with ultra clean water and ethanol and dried
under a N2 stream. SLBs were prepared by spin coating (45).
To form SLBs, a lipid chloroform mixture containing 1mM
POPC, 0.01mM Biotin Capped PE, supplemented with DiI,
was dropped on a spinning coverslip. SLBs were hydrated with
Hank’s Balanced Salt Solution (HBSS; Gibco) throughout the
preparation. After deposition, nonspecific binding was blocked
by incubation with 10 mg/ml BSA in HBSS. Subsequently,
SLBs were incubated with 0.5µg/ml streptavidin (Thermo
Fisher scientific). Finally, SLBs were incubated with 0.5µg/ml
biotinylated anti-human CD3 (OKT3)-ATTO647 for 15min at
RT, after which they were used directly for cell seeding.
Immunofluorescence
Immunofluorescent staining of CD3 was performed on
wildtype Jurkat T cells on microprinted antibody spots.
Immunofluorescent staining of phospho-tyrosine was performed
on wildtype Jurkat T cells on microprinted antibody spots and on
wildtype Jurkat T cells on SLBs. LFA-1 staining was performed
on wildtype Jurkat T cells on SLBs. Cells were seeded on spots
or SLBs for 15–30min at 37◦C. Samples were washed with
PBS and subsequently fixed with 4% PFA in PBS for 15min at
RT. After fixation, samples were blocked for 1 h with blocking
solution (PBS/3% BSA/10mM glycine/1% human serum) at
RT. For CD3 and phospho-tyrosine staining on antibody spots
and for phospho-tyrosine staining on SLBs, permeabilization
was performed simultaneously with blocking by adding 0.1%
saponin to the blocking solution. 0.1% saponin was added to
all subsequent antibody staining solutions. For LFA-1 staining,
after blocking, cells on SLBs were incubated with primary Mouse
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IgG1 anti-human LFA-1 antibody TS2/4 and subsequently Goat-
anti-Mouse-IgG1-Alexa488. For phospho-tyrosine staining,
after blocking/permeabilization, cells on antibody spots were
incubated with Mouse IgG1 p-Tyr-100-Alexa488; cells on
SLBs were incubated with primary Mouse IgG1 p-Tyr-100
and subsequently Goat-anti-Mouse-IgG1-Alexa488. For CD3
staining, after blocking/permeabilization, cells on antibody
spots were incubated with OKT3-biotin and subsequently
NeutrAvidin-Texas-Red. After immunofluorescence staining,
samples on microprinted antibody spots were washed with
phosphate buffer and embedded in Mowiol (Sigma-Aldrich).
Immunofluorescence samples on SLBs were not embedded
but imaged in PBS directly after preparation. To study the
effect of inhibition of actin polymerization on IS formation,
CD6-GFP Jurkat cells were taken from culture and incubated
in HBSS with or without 0.5µM Cytochalasin D for 15min
at 37◦C at a concentration of 800,000 cells per ml. Next, cell
suspensions were added onto αCD3-containing SLBs, reaching
a final cell concentration of 400,000 cells per ml. Samples
were incubated for 30min at 37◦C. After incubation, samples
were fixed with 4% PFA in PBS for 15min at RT. Finally
samples were washed once and imaged in PBS directly after
preparation. CD6-GFP, αCD3-ATTO647, DiI, and brightfield
signals were acquired. Samples of cells seeded on microprinted
antibody spots were imaged on an Olympus FV1000 confocal
laser scanning microscope with a 60× 1.35 NA oil immersion
objective. Samples of cytochalasin D treated cells on SLBs were
imaged using a Leica DMI6000 widefield microscope equipped
with a HC PL APO 63× 1.40 NA oil immersion objective.
Samples of LFA-1 and phospho-tyrosine staining in cells on
SLBs were imaged with TIRF microscopy at an Olympus IX-71
wide field fluorescence microscope equipped with a 3-line
TIRF system and a Hamamatsu ImagEM EM-CCD camera
equipped with a PL APO 60×/1.4 NA oil immersion TIRF
objective.
Live Cell Imaging on SLBs
Live cell imaging in cells on SLBs was performed at 37◦C
with TIRF microscopy at the Olympus TIRF microscope setup
described above. Prior to live cell imaging, Jurkat cells (LifeAct-
GFP or CD6-GFP) were washed with PBS and resuspended in
HBSS. Cells were added to the SLBs at the microscope, in a final
concentration of 400,000 cells per ml HBSS. Directly after adding
the cells, both cells and αCD3-ATTO647coupled to the SLBs were
imaged. Images were acquired at a frame rate of 300 ms/frame or
1 s/frame with an exposure time of 10–100ms.
Cell-Bead Contact Experiments
Dynal CD3 beads coated with mouse monoclonal anti-CD3
antibody (Invitrogen) or fibronectin-coated beads, all with a
diameter of 4.5µm, were used for bead experiments. Jurkat
CD6-GFP cells were seeded on fibronectin-coated coverslips
in imaging medium (RPMI 1640, 25mM HEPES, 0.5%
BSA). Subsequently, beads were added to the cells in a
concentration of 5µM. Imaging of the CD6-GFP signal and
the brightfield channel of cells with beads was performed
on a Zeiss LSM510 meta confocal laser scanning microscope
equipped with a PL APO 63×/1.4 NA oil immersion objective.
Cells were imaged at RT to slow down internalization of
the beads.
FRAP Measurements
All FRAP measurements were performed on a Zeiss LSM510
meta confocal laser scanning microscope equipped with a PL
APO 63×/1.4 NA oil immersion objective. For FRAP on antibody
spots, Jurkat CD6-GFP cells were resuspended in phenol red-
free medium, seeded onto microprinted surfaces and imaged at
37◦C. FRAP was performed using a 2.1µm diameter circular
region of interest (ROI). Photobleaching was performed at
100% laser power by scanning the bleached ROI for two
iterations, yielding a total bleach time of 0.10 s and an average
fluorescence loss of ∼50%. Recoveries were collected with
time intervals of 200ms using 488 nm excitation. Fluorescence
intensity data for the bleached ROI and a control ROI
were calculated using LSM software (Zeiss). After background
correction and normalization to t0 using a method that is
known as double normalization (46), the single post-bleach
curves were fitted using Origin (OriginLab) with the following
model:
I (t)=A∗e−t/τ (1)
where I(t) is the intensity in the bleached ROI at time t, A is the
mobile fraction, and τ is the characteristic recovery time. The
halftime recovery t0.5 was calculated with:
t0.5= ln2∗ τ (2)
For FRAP measurements on cells in contact with beads, Jurkat
CD6-GFP cells were resuspended in phenol red-free medium,
incubated with αCD3-coated beads and seeded on fibronectin-
coated surfaces. FRAP was performed using a 2 × 1µm
rectangular ROI. Photobleaching was performed at 100% laser
power by scanning the bleached ROI for 20 iterations, yielding
a total bleach time of 1 s and average fluorescence loss of
∼50%. Recoveries were collected with time intervals of 100ms
using 488 nm excitation. After background correction and single
normalization, FRAP curves were fitted using the Ellenberg
fitting (47) with the help of FRAPAnalyser software (48):
I (t)=Ifinal
(
1−(w2(w2+4piDt)
−1
)1/2
(3)
Where I(t) is the fluorescence intensity as a function of time, Ifinal
the final intensity reached after complete recovery, w the width
of the rectangular ROI, and D is the one-dimensional diffusion
constant. Recovery halftime t0.5 was calculated using the formula
(49):
D=
0.88w2
4t0.5
(4)
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Image Analysis
Image analysis was performed using Fiji Image J (50). To quantify
the immunofluorescence images of cells on microprinted spots,
a custom image analysis algorithm was used. Shortly, spots
were segmented based on an intensity threshold applied to
the spots channel. Cells were segmented using an edge finding
algorithm applied to the DIC image and a selection of objects
based on size. Next, the segmentations of the spots and cells
were combined resulting in masks for cellular parts covering
the spots and cellular parts covering the surrounding area.
These masks were subsequently used to measure the intensity
of the fluorescent protein or immunostaining on the spots and
the surrounding area. Enrichment of CD6 was quantified by
measuring the ratio of the fluorescent intensity in parts of the
cells covering the spots and the fluorescent intensity in parts of
the cells covering the surrounding area coated with fibronectin.
A value of 1 indicates no recruitment, while values higher or
lower than 1 indicate recruitment or exclusion, respectively.
In Jurkat CD6-GFP cells on SLBs, kymographs were created
along the indicated lines using the Dynamic Reslice option under
Image>Stacks in FIJI Image J for the indicated time periods.
Co-localization of CD6-GFP and αCD3 during immunological
synapse formation was determined using the JACoP plugin
in FIJI Image J (51). A ROI in the central part of the cell-
SLB interface was selected and the same size ROI was applied
to each time point and to all cells analyzed. Co-localization
was quantified by determining the Mander’s Coefficient M1 by
making use of appropriate thresholding which only included
CD6- and αCD3-rich microclusters or the cSMAC. Also the
Mander’s Coefficient M2 (with same thresholding as for M1)
and the Pearson Coefficient over time were determined. Relative
CD6-GFP signal intensity in the same ROI over time was
determined by calculating the integrated density of the total
ROI and relating it to the integrated density at t = 2min
(start of immunological synapse formation). The fraction of cells
forming an immunological synapse on SLBs upon Cytochalasin
D treatment was determined by manual counting. Cells having
formed an immunological synapse were defined as CD6-GFP
positive cells, also visible in brightfield, on top of SLB (DiI-
positive area), overlaying an αCD3 positive cluster. In bead
experiments, CD6 enrichment was determined as the ratio
between CD6-GFP fluorescence intensity of the membrane area
of cell that was in contact with the bead and the fluorescence
intensity in an equal sized ROI in the membrane of the cell at
the opposite side of bead contact.
Statistical Analysis
Statistical analysis was carried out with GraphPad Prism version
5.03. Data are presented as mean ± standard deviation for bar
plots andmedian± interquartile range for box plots. To compare
two groups, a paired/unpaired t-test was applied. To compare
three or more groups, one-way ANOVA with post-hoc Tukey’s
Multiple Comparison test or Kruskal–Wallis test with post-hoc
Dunn’s Multiple Comparison test was applied. Differences were
considered statistically significant at p< 0.05.
RESULTS
CD6 and TCR/CD3 in Jurkat T Cells
Co-localize Upon Ligation Through
Micropatterned Antibody Spots
Although CD6 has been recognized as a TCR co-receptor,
the nature of the interaction with the TCR/CD3 complex has
not been resolved. To provide a biophysical characterization
of the interplay of these receptors during IS formation,
we first studied CD6 and TCR/CD3 (co-)localization using
antibody spots created with microcontact printing (Figure 1)
(52). Wildtype Jurkat T lymphoma cells were seeded on
microprinted antibody spots (5µm in diameter) that were
composed of 100% αCD6 or different concentrations of αCD3 (1-
10-100%; diluted with mouse IgG2A-isotype control antibody)
surrounded by fibronectin. Intracellular signaling through
phospho-tyrosine (pTyr) was visualized by immunofluorescence
staining on fixed cells (Figure 1A). Clustering of CD3 led to
intracellular signaling as quantification of the pTyr fluorescence
intensity levels in parts of the cells that covered the spots
demonstrate a concentration-dependent increase on αCD3
spots (Figure 1B). Cells seeded on 1% αCD3 spots did not
show any significant increase in pTyr levels compared to the
100% fibronectin (FN) spots (negative control) (Figure 1B).
Next to clustering of CD3 also clustering of CD6 (using
100% αCD6 spots) induced T cell signaling; pTyr intensity
on 100% αCD6 spots is comparable to the pTyr intensity
on 10% αCD3 spots and significantly different from the
intensity on 1% αCD3 and 100% FN spots. These results
show that sufficient levels of cross-linking of CD3 or CD6 by
microprinted antibody spots induce T cell signaling by increasing
pTyr levels, an event generally leading to activation of Jurkat
T cells.
To investigate the recruitment of CD6 upon cross-linking
of the TCR/CD3 complex, we created Jurkat T cells stably
expressing CD6-RFP or CD6-GFP. Total cell surface expression
of CD6 as well as GFP and RFP expression in CD6-GFP
cells, CD6-RFP cells and wildtype cells was determined with
flow cytometry (Supplementary Figure 1). CD6-RFP Jurkat
T cells were seeded onto the microprinted antibody spots
(Figures 1C,D). As expected, confocal microscopy images show
a strong recruitment of CD6-RFP to 100% αCD6 spots.
Furthermore, a concentration-dependent recruitment of CD6-
RFP was observed on 1–100% αCD3 antibody spots (Figure 1C).
Quantification of CD6-RFP enrichment on the spots confirmed
the concentration-dependent effect of αCD3 antibody in
the spots on CD6-RFP enrichment. Also, CD6 enrichment
to spots containing 100% αCD3 was comparable to that
observed in the positive control, 100% αCD6 spots (Figure 1D).
These results demonstrate that cross-linking of the TCR/CD3
complex induces recruitment of CD6 to spots. Consequently,
we investigated whether cross-linking of CD6 also induces
recruitment of the TCR/CD3 complex. To this end, wildtype
Jurkat T cells were seeded on the microprinted antibody spots
and stained for endogenous TCR/CD3 complex recruitment
using a biotinylated αCD3 antibody and fluorescently labeled
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FIGURE 1 | CD6 and TCR/CD3 in Jurkat T cells co-localize upon ligation through micropatterned antibody spots. (A,B) Wildtype Jurkat T cells were seeded on
micropatterned substrates containing 100, 10, or 1% αCD3 spots, 100% αCD6 spots or 100% fibronectin (FN) spots, surrounded by fibronectin, fixed after 15min
and stained for phospho-tyrosine. All spots were labeled with Alexa647, phospho-tyrosine was labeled with Alexa488. Representative confocal images are shown in
(A), quantification of phospho-tyrosine intensity in the spot area of n = 10 cells per condition is shown in (B). Bars represent mean with SD. Statistical significance was
tested with one-way ANOVA with post-hoc Tukey’s Multiple Comparison test. (C,D) CD6-RFP Jurkat T cells were seeded on micropatterned substrates containing
100, 10, or 1% αCD3 spots, or 100% αCD6 spots, surrounded by fibronectin, and fixed after 15min. All spots were labeled with Alexa647. Representative confocal
images are shown in (C), quantification of CD6 enrichment of n = 10 cells per condition is shown in (D). CD6 enrichment is defined as the ratio between CD6-RFP
intensity of parts of the cell on the spot vs. part of the cell covering the surrounding fibronectin. Bars represent mean with SD. Statistical significance was tested with
Kruskal–Wallis test with post-hoc Dunn’s Multiple Comparison test. (E,F) Wildtype Jurkat cells were seeded on micropatterned substrates containing 100, 10, or 1%
αCD3 spots, or 100% αCD6 spots, surrounded by fibronectin, fixed after 15min and stained for CD3. All spots were labeled with Alexa647, CD3 was labeled with
TexasRed. Representative confocal images are shown in (E), quantification of CD3 enrichment of n = 10 cells per condition is shown in (F). Bars represent mean with
SD. CD3 enrichment is defined as the ratio between CD3 intensity of parts of the cell on the spot vs. part of the cell covering the surrounding fibronectin. Statistical
significance was tested with Kruskal–Wallis test with post-hoc Dunn’s Multiple Comparison test. Scale bars represent 10µm; *p < 0.05; **p < 0.01; ***p < 0.001.
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NeutrAvidin (Figures 1E,F). As expected, the TCR/CD3 complex
was recruited to αCD3 spots, even at concentrations as low as
1% αCD3. Vice versa, CD3 was also recruited to 100% αCD6
spots, suggesting that the TCR/CD3 complex interacts with and
co-migrates with CD6 (Figures 1E,F).
CD3 Ligation on Micropatterned Antibody
Spots Causes Immobilization of CD6
Next, we set out to investigate whether ligation of the
TCR/CD3 complex on microprinted antibody spots influenced
CD6 lateral mobility. To this end, CD6-GFP Jurkat T cells
were seeded onto microprinted antibody spots composed of
different concentrations of αCD3 (1-10-100%) (Figure 2A). To
study CD6 mobility upon TCR/CD3 complex immobilization,
fluorescence recovery after photobleaching (FRAP) of CD6-
GFP was performed by bleaching circular 2.1µm regions
of interest (ROIs) both on spots and on fibronectin-coated
areas surrounding these spots (Figure 2B). At the interface
between cell and antibody spot-covered surface, FRAP revealed
partial immobilization of CD6-GFP on 10 and 100% αCD3
spots, but not on 1% αCD3 spots (Figure 2C); a CD6-
GFP fraction of ∼30% was immobilized on 10 and 100%
αCD3 spots, significantly different from the immobile CD6-
GFP fraction on 1% αCD3 spots (appr. 10%), which was
comparable to the immobile fraction on surrounding fibronectin-
coated areas (Figures 2E,F). In comparison, FRAP outside
antibody spot areas (on surrounding fibronectin-coated areas)
showed unrestricted mobility of CD6-GFP with no effect of
the αCD3 concentration within the spots (Figures 2D,F). The
diffusion speed of the mobile CD6-GFP fraction was not
affected by CD3 immobilization, as both on αCD3 spots and
on surrounding fibronectin-coated areas recovery halftimes were
similar (Figures 2G,H). These data indicate that a subpopulation
of CD6 is immobilized upon CD3 ligation and confirm that CD6
at least partially interacts physically with the TCR/CD3 complex.
CD6 Is Co-transported With TCR/CD3 in
Microclusters Toward the cSMAC of the
Immunological Synapse Formed on
αCD3-Containing SLBs
When a T cells engages contact with a stimulating antigen-
presenting cell, the TCR/CD3 complex is transported to the
center of the immunological synapse (IS) formed at the interface
between these cells. CD6 has been previously shown to co-localize
with the TCR/CD3 complex in the central supramolecular
activation cluster (cSMAC) of this IS (29, 35). However,
techniques exploited so far have only shown static co-localization
of CD6 and TCR/CD3 complex at a fully matured IS. Therefore,
to investigate the dynamics of the CD6-TCR/CD3 complex
interplay during IS formation, we studied synapse formation in
Jurkat T cells seeded on planar supported lipid bilayers (SLBs),
a well-established and widely used system to study early steps
of IS formation (1, 3, 6, 11, 42). SLBs containing biotinylated
lipids were prepared by spin coating lipids directly from
chloroform solutions onto glass coverslips (45). Subsequently,
ATTO647-labeled, biotinylated αCD3 antibody was coupled to
the biotinylated lipids in the SLB via streptavidin, leading to free
lateral diffusion of αCD3 antibody, confirmed by FRAP (data not
shown).
To assess whether Jurkat T cells formed an IS on these αCD3-
containing SLBs, wildtype cells were allowed to interact with
and spread on the SLBs. After fixation, the αCD3 antibody in
the lipid bilayer was visualized to localize TCR/CD3 complexes.
Representative brightfield images overlaying αCD3 signal are
shown in Supplementary Figure 2. Wildtype Jurkat T cells
were stained for phospho-tyrosine, to visualize signaling, and
for integrin LFA-1, a classical component of the peripheral
supramolecular activation cluster (pSMAC) surrounding the
cSMAC in the IS (7). Furthermore, LifeAct-GFP Jurkat T cells
were seeded onto SLBs to visualize the actin cytoskeleton
(Figures 3A–C). Total Internal Reflection Fluorescence (TIRF)
microscopy images of αCD3 in SLBs show that Jurkat T cells
formed a large central cluster (cSMAC) containing TCR/CD3
in contact with SLBs (Figures 3A–C, left panels). Clustering
of TCR/CD3 through αCD3 engagement in SLBs was able to
mediate signaling as shown by the pTyr staining that co-localized
with the αCD3 antibody in SLBs (Figure 3A). Staining of LFA-
1 confirmed the formation of a typical peripheral ring (pSMAC)
surrounding the cSMAC (Figure 3B). Also, typical exclusion of
actin from the cSMAC region was seen in LifeAct-GFP Jurkat
T cells on SLBs (Figure 3C). Overall, these data indicate that
SLBs containing αCD3 allowed IS formation in interacting Jurkat
T cells.
Next, we investigated the dynamics of CD6-TCR/CD3
interplay during synapse formation. To this end, Jurkat cells
expressing CD6-GFP were imaged during spreading on and
engagement of contact with SLBs using live cell TIRFmicroscopy
(Figure 3D and Supplementary Video 1). Within 2min after
initial contact of the cell with the SLB, TCR/CD3 microclusters
could be observed that were radially transported from the cell
periphery toward the center of the cell-SLB interface (Figure 3D,
top row). After 5min a large, bright, and stable TCR/CD3-
rich central cluster, the cSMAC of the IS, was formed on
the SLB. During cell spreading in the first 3min, CD6-GFP
in the plasma membrane spread out and formed a peripheral
ring-like pattern (Figure 3D, middle row). Within this ring,
microclusters containing CD6-GFPwere present, co-localizing to
αCD3 microclusters formed in the SLB (Figure 3D, bottom row;
Figure 3E). Kymograph analysis of the cross section indicated
in the merged image at timepoint 4min in Figure 3D (during
3min and 45 s to 6min and 12 s after initiation of cell-SLB
contact) revealed that these microclusters, containing both CD6
and TCR/CD3, were transported from the periphery toward
the central region (cSMAC) of the IS (Figure 3F). After 4min
the CD6-GFP ring started to disappear as a result of constant
transport of microclusters toward the cSMAC. Thereafter a large,
bright cluster of CD6-GFP was visible at the center of the cell-
SLB interface, which largely co-localized with the TCR/CD3-
rich cSMAC (Figure 3D, middle and bottom row). Intensity
and co-localization analysis of the central part of the cell-SLB
interface was performed for multiple cells (representative ROI is
shown in Figure 3E). CD6-GFP signal intensity increased in the
center of the cell over time, indicating continuous recruitment of
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FIGURE 2 | CD3 ligation on micropatterned antibody spots causes immobilization of CD6. (A–H) CD6-GFP Jurkat T cells were seeded on micropatterned substrates
containing 100, 10, or 1% αCD3 spots, created using microcontact printing, surrounded by fibronectin. All spots were labeled with Alexa647. Schematic
representation of the set-up of the experiment and positioning of the FRAP region are shown in (A,B) respectively. (C–H) FRAP was performed on CD6-GFP covering
the antibody spots and on CD6-GFP covering surrounding fibronectin. Fluorescence intensity of CD6-GFP in the FRAP region on the antibody spots or on the
surrounding fibronectin is shown in (C,D) respectively. Curves represent the mean of ≥13 measurements ± SEM. Individual FRAP curves were fitted with a single
exponential model and values for the mobile fraction and the recovery half time for each separate curve were determined. Mobile fraction values on antibody spots
and on surrounding fibronectin are shown in (E,F) respectively. Lines indicate median with the interquartile range represented as black bars. Statistical significance
was tested with one-way ANOVA with post-hoc Tukey’s Multiple Comparison test. Recovery halftime values on antibody spots and on surrounding fibronectin are
shown in (G,H) respectively. Lines indicate median with the interquartile range represented as black bars. **p < 0.01.
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FIGURE 3 | CD6 is co-transported with TCR/CD3 in microclusters toward the center of the immunological synapse formed on αCD3-containing SLBs. (A,B)Wildtype
Jurkat T cells were seeded for 30min on SLBs containing ATTO647-conjugated αCD3, and subsequently fixed and stained for immunological synapse markers.
Representative TIRF microscopy images for phospho-tyrosine staining and LFA-1 staining (both labeled with Alexa488) are shown in (A,B) respectively.
(C) LifeAct-GFP Jurkat T cells were seeded for 30min on SLBs containing ATTO647-conjugated αCD3 and imaged using live cell imaging TIRF microscopy.
Representative images are shown in (C). (D–G) CD6-GFP Jurkat T cells were imaged while settling on a SLB containing ATTO647-conjugated αCD3, using TIRF
microscopy live cell imaging. Snap shots of every minute of the time lapse are shown in (D). Snap shots at time point 3min, including a zoom-in of CD6-GFP and
αCD3 microclusters are shown in (E). Kymograph of the line (indicated in the Merge image at time point 4min in D) during 3:45 to 6:12min of the imaging period is
shown in (F). Co-localization over time starting at time point 2min, represented as Mander’s coefficient M1 (fraction of CD6-GFP overlapping with αCD3) in the central
zoomed-in region indicated in (E) is shown in (G). Scale bars represent 10µm.
CD6-GFP to the cSMAC (Supplementary Figure 3A). Also, co-
localization of CD6-GFP and TCR/CD3 increased as the fraction
of CD6-GFP overlapping with αCD3 (Mander’s coefficient M1)
increased over time (Figure 3G), as well as the Pearson coefficient
and Mander’s coefficient M2 (fraction of αCD3 overlapping
CD6-GFP) (Supplementary Figures 3B,C). Of note, engagement
of CD6 did not seem to affect IS formation, as pre-treatment
and incubation of CD6-GFP Jurkat T cells with soluble human
ALCAM-Fc did not lead to a difference in the fraction of cells
forming a typical cSMAC within 30min after seeding on SLBs
(Supplementary Figure 4). Taken together, these data indicate
that a fraction of CD6 molecules in the T cell membrane
constantly associate with the TCR/CD3 complex from the
very early moment of SLB engagement, until the formation
of the mature cSMAC, where CD6-GFP is continuously being
recruited. Thus, CD6 seems to be a member of the microclusters
containing TCR/CD3, and is co-recruited with TCR/CD3 in these
microclusters toward the IS.
Disruption of Actin Polymerization Inhibits
TCR/CD3 and CD6 Co-transport Toward
the cSMAC of the Immunological Synapse
on αCD3-Containing SLBs
The actin cytoskeleton provides a dynamic mechanical
framework to spatially organize the IS, and the radial transport
of TCR/CD3 microclusters is dependent on retrograde actin flow
(10, 11, 53). To investigate whether transport of CD6 toward the
cSMAC also depends on an intact actin cytoskeleton, Jurkat CD6-
GFP cells were treated with 0.5µM of the actin polymerization
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inhibitor cytochalasin D (CytoD) for 15min before allowing
them to interact with αCD3-containing SLBs. CD6 and
TCR/CD3 microcluster formation and transport were imaged
by TIRF microscopy (Figure 4 and Supplementary Video 2).
In cytochalasin D-treated cells, microclusters of both CD6 and
the TCR/CD3 complex were still formed after inhibition of actin
polymerization (Figure 4A). However, these clusters were static
and not transported toward the center of the cell-SLB interface,
as in untreated cells shown in Figure 3D. Indeed, kymograph
analysis shows that the position of peripheral clusters in the
cross section indicated in the merged image at timepoint 0min
in Figure 4A is stable over time, as represented by the horizontal
line in both the αCD3 and the CD6 channel (Figure 4B). In
addition, some CD6 microclusters did not co-localize with
TCR/CD3 microclusters. Although not completely immobile,
these clusters did not move toward the center of the contact
(Figure 4B). Moreover, treatment of cells with CytoD resulted
in less Jurkat T cells forming a typical cSMAC within 30min
after SLB engagement and cell spreading (Figure 4C). This
resulting difference may be an underestimation of the effect, as
it is possible that CytoD-treated cells that did not engage the
SLB at all have been washed away during fixation. In conclusion,
these data demonstrate that the transport, but not the formation
of CD6-TCR/CD3 microclusters clearly depends on actin
polymerization.
Interaction With αCD3-Coated Beads
Causes CD6 Clustering and Immobilization
at Cell-Bead Interface
To better understand CD6 mobility in a cell-cell contact
model, magnetic beads coated with αCD3 or with FN were
added to CD6-GFP Jurkat T cells seeded on a FN-coated
surface and CD6 enrichment at the cell-bead interface was
FIGURE 4 | Disruption of actin polymerization inhibits TCR/CD3 and CD6 co-transport toward the cSMAC of the immunological synapse on αCD3-containing SLBs.
(A,B) CD6-GFP Jurkat T cells, either untreated or pretreated with 0.5µM Cytochalasin D for 15min, were seeded on a SLB containing ATTO647-conjugated αCD3.
Twenty minutes after seeding CD6-GFP and αCD3 dynamics were imaged using TIRF microscopy live cell imaging. Snap shots of every 30 s of the time lapse are
shown in (A). Kymograph of the line (indicated in the Merge image at time point 0min in A) during the whole imaging period (4.5min) is shown in (B). (C) Wildtype
Jurkat T cells, either untreated or pretreated with 0.5µM Cytochalasin D for 15min, were seeded for 30min on SLBs containing ATTO647-conjugated αCD3, and
subsequently fixed. Widefield microscopy was performed and cells (>44 cells per condition; three independent experiments) were scored for synapse formation
based on identification of cells by brightfield displaying αCD3 positive cluster formation in a lipid bilayer (DiI) positive area. Average percentages of cells forming an
immunological synapse are represented in (C). Bars represent mean with SD. Statistical significance was tested with paired t-test. Scale bar represents 10µm;
*p < 0.05.
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determined. Brightest point reconstructions of confocal image
stacks of CD6-GFP show that CD6 was a threefold more
enriched to αCD3-coated beads than to fibronectin-coated
beads (Figures 5A,B). Next, CD6 mobility was assessed using
FRAP. FRAP measurements on CD6-GFP were performed on
cells incubated with magnetic αCD3 beads, either at the cell-
bead interface (bead side) or at the opposing free side of the
cell (no bead side) (Figure 5C; FRAP on cells with beads).
Of note, in this set-up, diffusion of CD6-GFP was assessed
in a vertically oriented membrane and therefore 2 × 1µm
rectangular regions of interest (ROIs) were used for FRAP, in
contrast to circular ROIs used on horizontal orientedmembranes
in Figure 2. As controls, CD6-GFP Jurkat T cells without beads,
either untreated or incubated with soluble αCD3 were used for
FRAP measurements (Figure 5C; FRAP on cells without beads).
Resulting mobile fractions indicate that, as for CD6-GFP on
10 and 100% αCD3 antibody spots, a significant larger portion
of the CD6-GFP population was immobilized at the cell-bead
interface for cells in contact with αCD3-coated beads compared
to CD6-GFP in the opposing side not in contact with a bead
(Figure 5D). The mobile CD6-GFP fraction on the no bead site is
comparable to that in untreated cells or cells treated with soluble
αCD3. Again, the mobility of the mobile CD6-GFP fraction
was not affected by interaction with the αCD3-coated bead, as
recovery halftimes for all conditions did not differ significantly
(Figure 5E). To determine the stability of this CD6-TCR/CD3
complex at the cell-bead interface, electromagnetic tweezers were
used to displace the αCD3-coated bead through mechanical
force (Supplementary Figure 5) (54). These data suggest that
CD6 follows displacement of TCR/CD3 clusters and that the
association between CD6 and TCR/CD3 complex is mechanically
stable when exposed to mechanical forces of in the 200–900 pN
range. Collectively these results confirm previous observations
on microprinted antibody spots: cross-linking the TCR/CD3
complex by immobilized αCD3 results in immobilization of
a significant fraction of CD6-GFP molecules, which strongly
indicates a stable interaction between CD6 and the TCR/CD3
complex.
DISCUSSION
In this study, we applied different experimental techniques
to characterize the interplay between CD6 and the TCR/CD3
complex. We show that CD6 and the TCR/CD3 complex are
co-recruited to stable stimulatory clusters, both in Jurkat T cells
seeded on antibody spots and in Jurkat T cells in contact with
αCD3-coated beads. This association to TCR/CD3 applies to only
a fraction of the CD6 population, as FRAP measurements on
CD6-GFP (both in cells on αCD3 antibody spots or in cells in
contact with αCD3-coated beads) indicate that more than half of
the CD6-GFP population was still mobile. If the interaction was
transient, a reduction in recovery time but no change in immobile
fraction would have been expected. This partial association of
CD6 with TCR/CD3 confirms previous reports by Gimferrer
and colleagues which showed a partial association using co-
precipitation (35). Although substantial, the fully mobile and
non-associated fraction CD6 of ∼70% reported here may be an
overestimation, as we made use of an over-expression model
that most probably leads to an excess of CD6. This interaction
between CD6 and TCR/CD3 seems mechanically rather stable,
as we could show that CD6 follows displacement of TCR/CD3
by moving αCD3-coated magnetic beads with electromagnetic
forces of 200–900 pN.
Next to recruitment to static ligands, we exploited SLBs where
αCD3 could freely diffuse in the lateral plane. This setup allowed
us to visualize CD6 dynamics during IS formation. We found
that CD6 co-localizes with TCR microclusters on the Jurkat
T cell membrane during IS formation. These CD6-TCR/CD3
microclusters were transported toward the cSMAC of the IS,
which finally resulted in CD6-TCR/CD3 co-localization in the
mature IS, as reported previously by us and others (29, 35).
Since it has been shown that TCR signaling predominantly takes
place in these microclusters that localize outside the cSMAC
(1, 2, 12), the presence of CD6 in these microclusters suggests
a role for CD6 in TCR receptor (co-)signaling. In our SLBs no
ligand for CD6 was present; the co-localization of CD6 with
TCR/CD3 microclusters we have demonstrated in this study is
therefore independent of direct CD6 ligand binding. Therefore,
although CD6-ALCAM interactions have been shown to localize
to the cSMAC in stable T cell-DC interactions (29, 35), we
cannot exclude that ligand binding affects the preceding CD6-
TCR/CD3 co-localization in microclusters during IS formation
and transport toward the cSMAC. Whether TCR/CD3 and CD6
interact directly or indirectly remains to be determined. Direct
interaction between CD6 and TCR/CD3 is deemed unlikely, as
the dimensions of receptor-ligand interactions differ; the optimal
distance for TCR-pMHC is calculated to be 14–15 nm, whereas
the binding distance between CD6 and ligand ALCAM would be
probably larger than 21 nm (31).
Furthermore, in all set-ups we have used antibodies directed
against CD3 to induce TCR/CD3 clustering and triggering.
Although this is an artificial way of inducing T cell activation,
it has been shown that stimulating CD3, without presence of an
MHC-antigen complex, can sufficiently induce IS formation in
Jurkat T cells (11). Furthermore, it has been shown that CD6
is phosphorylated on its cytoplasmic tail upon cross-linking of
CD3 and CD2/CD3 co-cross-linking (34). TCR/CD3 complex
triggering using αCD3 antibodies may result in differential
downstream signaling than triggering with specific peptide-MHC
complexes. As the association between CD6 and TCR/CD3
may depend on phosphorylation of CD3 and/or CD6 and
could lead to different proteins interacting with CD3 and/or
CD6, the type of molecule triggering the TCR/CD3 complex
(αCD3 or pMHC complex) might modulate the CD6-TCR/CD3
interaction. Investigation of co-localization of CD6 cytoplasmic
tail mutants with TCR/CD3 microclusters during IS formation
would be able to shed more light on this question.
The actin cytoskeleton provides a dynamic mechanical
framework to spatially organize the IS, and the radial transport
of TCR microclusters depends on retrograde actin flow (10,
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FIGURE 5 | Interaction with αCD3-coated beads causes CD6 clustering and immobilization at cell-bead interface. (A,B) CD6-GFP Jurkat T cells together with
fibronectin (FN)-coated or αCD3-coated beads were seeded on a fibronectin-coated surface. Representative brightfield and confocal fluorescence images of live cell
imaging are shown in (A). CD6-GFP images are brightest point reconstructions of z-stacks, allowing display of CD6 distribution of the entire cell. Quantification of CD6
enrichment at cell-bead interface is shown in (B). CD6 enrichment (n = 10 cells per condition) is determined as the ratio between the area of cell that is in contact with
the bead and an equal area at the opposite side of bead contact. Bars represent mean with SD. Statistical significance was tested with unpaired t-test. (C–E)
CD6-GFP Jurkat T cells incubated with FN-coated or αCD3-coated beads or soluble αCD3 were seeded on a fibronectin-coated surface. Schematic representation of
FRAP regions is depicted in (C). FRAP was performed on CD6-GFP in cells with beads, at parts of the cell not in contact or in contact with the bead (respectively left
and right in right panel in C) and compared with cells without beads, either untreated or treated with soluble αCD3 antibodies (respectively left and right in left panel in
C). Individual FRAP curves (n ≥ 14 measurements per condition) were fitted with a single exponential model and values for the mobile fraction and the recovery half
time for each separate curve were determined. Mobile fraction values and recovery halftime values of single FRAP curves for all conditions are shown in (D,E),
respectively. Lines indicate median with the interquartile range represented as black bars. Statistical significance was tested with one-way ANOVA with post-hoc
Tukey’s Multiple Comparison test. Scale bars represent 10µm; **p < 0.01; ***p < 0.001.
11, 53). Also in our set-up actin was present in a peripheral
ring on the intracellular side of the IS and excluded from the
cSMAC. Furthermore, we found that the CD6-TCR/CD3 co-
transport in microclusters toward the cell center depends on
actin polymerization. This suggests that CD6, similar to the
TCR/CD3 complex, is linked to the actin cytoskeleton. Moreover,
the peripheral ring-like pattern of CD6 we saw during the initial
cell spreading is reminiscent of the F-actin pattern observed in
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other studies on T cells forming an IS (11). The actin cytoskeleton
itself might even provide the link between CD6 and TCR/CD3.
Interestingly, CD6 has been shown to associate with the adaptor
protein SLP-76, which is part of TCR microclusters (13, 33,
55). TCR-induced tyrosine phosphorylation of SLP-76 has been
shown to be important in the recruitment of the proteins Nck
and WASp to TCR microclusters for actin polymerization (56).
However, CD6 association to the TCR/CD3 complex through
SLP-76 cannot explain CD6-TCR/CD3 co-transport into the
cSMAC, as it has been shown that SLP-76 (together with ZAP70)
dissociates from TCR microclusters before these coalesce with
the cSMAC, and localizes to unidentified perinuclear structures
(13, 55).
Next to SLP-76, CD6 also interacts with the actin-binding
adaptor protein syntenin-1 (57). Syntenin-1 has been implicated
in functional asymmetry in T cells and actin polymerization and
accumulation in T cell activation (58, 59). Presence of syntenin-
1 is needed for CD3 accumulation at the cSMAC (59), and
may provide the link between CD6 and the TCR/CD3 complex,
in this way facilitating CD6-TCR/CD3 microcluster transport
toward the cSMAC. Unlike SLP-76, syntenin-1 has been shown
to localize to the cSMAC of the IS, where it co-localizes with
CD6 and TCR/CD3 (57). Any possible link between CD6 and the
TCR/CD3 via syntenin-1 would, however, be independent of the
actin cytoskeleton, as the cSMAC is devoid of actin (11).
Detailed investigation of the organization of CD6, TCR/CD3,
SLP-76 during IS formation using super-resolution imaging,
such as Sherman and colleagues showed for the TCR, LAT,
ZAP-70, and SLP-76 (60), could provide more insight into the
organization of these TCR-CD6 microclusters and the exact
role of SLP-76 and syntenin-1 in the interaction between
these cell surface receptors. Next to that, super-resolution
microscopy would also be able to shed light on the hitherto
open question whether CD6 and TCR/CD3 associate directly
or indirectly at the steady state level in the cell membrane
of a resting T cell. New possible interaction partners of CD6
are still being identified and crucial molecules linking CD6
to the TCR/CD3 complex at the steady state level and/or
during IS formation may therefore be still unknown at present
(61).
Although the data presented here further substantiate the
interplay between CD6 and TCR/CD3 and indicate that this
co-recruitment already occurs in TCR microclusters prior
to stable IS formation, it still remains a subject of debate
whether CD6 signaling plays a stimulatory or inhibitory role
in T cell activation. On the one hand, many studies employing
monoclonal antibodies or soluble CD6 to target CD6 or its
interaction with ALCAM have underlined the stimulatory role of
CD6 in T cell activation and proliferation (23–29). On the other
hand, the mere presence of CD6 in the T cell membrane has
inhibitory effects on calcium response and IL-2 release in TCR-
activated Jurkat T cells (30). Also, CD6 associates with family
member CD5 (19), an established inhibitor of T cell signaling
(62), which may in fact indirectly give CD6 its inhibitory
capacities (31). It has been proposed that CD6 acts as a decoy
receptor to capture downstream signaling molecules away from
the TCR signaling complex, as it localizes to the cSMAC of the
IS, an area where TCR signaling is terminated through TCR
endocytosis and degradation (31, 63). However, our data show
that preceding formation of a stable mature IS, CD6 already co-
localizes with TCR/CD3 microclusters, which are believed to be
stimulating T cell activation. Still, CD6 may compose its own
signaling hub independent of the TCR/CD3-LAT signalosome,
as a proteomics study by Roncagalli and colleagues showed that
LAT is dispensable for CD6-SLP-76 association (64). Because
the CD6 gene has been shown to subject to alternative splicing
upon T cell activation, the role of CD6 may alter during T cell-
APC interaction, as one of the alternatively spliced forms has
been shown to no longer translocate to the IS (65–67). In
this study we have made use of full-length CD6 in our over-
expression models. Therefore, investigation of the localization of
alternatively spliced CD6 forms during IS formation, together
with functional read-outs such as calcium fluxing and T cell
proliferation, might provide more insight in the role of CD6 in
microcluster formation and the mature IS.
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